Search Results for "Cancer Diagnostics"

05:37 EST 22nd December 2014 | BioPortfolio

Original Source: Lab21 Launches New Lung Cancer Diagnostic Service

Cambridge, UK – 16 February 2012 - Lab21 Limited, the global specialist in personalised medicine and clinical diagnostics has launched a new Companion Diagnostic testing service for non-small cell lung cancer patients. The EML4-ALK companion diagnostic test for translocations in the ALK gene will allow physicians to select lung cancer patients likely to respond to ALK inhibitor therapy. The test uses proprietary PCR technology and will be performed in Lab21’s accredited laboratories in ...

Matching Channels

Roche

Roche is the 5th largest pharmaceutical company in the world, based on annual sales, which were recorded at $36,017m in 2009. The pharmaceutical products of Roche are major players in the followin...

Penile Cancer

Laryngeal Cancer

Nasopharyngeal Cancer

Rectal cancer

Matching News

Rna Diagnostics awarded patent for test that guides cancer chemotherapy

TORONTO,ON – Canadian molecular diagnostics developer Rna Diagnostics Inc., has been awarded a broad patent for its RNA Disruption Assay™ (RDA) in Australia for “Method of using Tumour RNA I...

2014-2018 UK Tumor Marker Testing Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies

"2014 Opportunities in the UK Cancer Diagnostics Market” is a new strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years.  The...

2014-2018 US Tumor Marker Testing Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies

"2014 Opportunities in the US Cancer Diagnostics Market” is a new strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years.  The...

PDI subsidiary Interpace Diagnostics enters molecular diagnostics market with thyroid and pancreatic cancer test portfolio acquisition

PDI, a leading healthcare commercialization company, announced that its Interpace Diagnostics subsidiary has entered the expanding cancer molecular diagnostics market with the acquisition of the miRIn...

Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets

(PRWEB) July 29, 2014 The “Tissue Diagnostics Market by Technology (Immunohistochemistry, in Situ Hybridization, Digital pathology & Workflow, Special Staining), Disease (Breast Cancer, Ga...

2014-2018 World Cancer Diagnostics Market Overview: Test Volume and Sales Forecasts by Country

This report provides a worldwide overview of the cancer diagnostics market, including mortality statistics and scientific views on the etiology of major types of cancer, estimates of the number of lab...

GeneNews raises $Cdn7.2mm through private placement

GeneNews Ltd. (molecular diagnostics for cancer) grossed $Cdn7.2mm ($6.7mm) through the private sale of 7mm common shares at $Cdn1.03, a 13% discount. The company will use the proceeds to help its US-...

Asuragen signs cancer panel deal with Janssen Diagnostics

Asuragen has agreed to make its SuraSeq next-generation sequencing cancer panels available to Janssen Diagnostics' customers  -More- 

Matching PubMed Articles

Innovations in Cervical and Endometrial Cancer.

The S2k guideline "Diagnostics and Therapy for Cervical Cancer" published in 2008 is currently being revised to the S3 level. Current developments in epidemiology, surgical therapy, radiochemotherapy ...

From the guest editor: into the era of personalized cancer diagnostics.

Criteria of the molecular pathology testing of lung cancer.

From the aspect of the contemporary pathologic diagnostics of lung cancer the tissue obtained is a key issue since small biopsies and cytology still play a major role. In the non-small cell lung cance...

Predictions for the future of kallikrein-related peptidases in molecular diagnostics.

Kallikrein-related peptidases (KLKs) form a cancer-related ensemble of serine proteases. This multigene family hosts the most widely used cancer biomarker that is PSA-KLK3, with millions of tests perf...

Current and proposed molecular diagnostics in a genitourinary service line laboratory at a tertiary clinical institution.

The idea that detailed knowledge of molecular oncogenesis will drive diagnostic, prognostic, and therapeutic clinical decision making in an increasingly multidisciplinary practice of oncologic care ha...

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement